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Abstract Pyrido-oxazine derivatives have been synthesized employing 
tandem SN2 and SNAr reaction between 2,4,6-tribromo-3-(2-
bromoethoxy)pyridine or 2,4,6-tribromo-3-(3-bromopropoxy)pyridine and 
variety of primary amines. Moderate to good regioselectivity in favor of 
cyclization at 2-position is observed. Pyrido-oxazine products thus 
generated are converted to biarylated pyrido-oxazine and terpyridine 
ligands. 
Key words pyridine, terpyridine, pyrido-oxazines, Suzuki coupling, 
Stille coupling. 
 
Pyridine is one of the important heterocycles, often 
encountered in natural products, bioactive molecules, and 
therapeutic drugs and also serves as common synthetic 
building block.1 There is a demand for reactions that allow 
direct functionalization of pyridine. Phenanthroline, 
bipyridine, terpyridine (Figure 1) and their derivatives 
have been extensively used as organic ligands with variety 
of metals to perform important synthetic transformations.2 
Pyrido-oxazines are class of heterocycles where one of the 
carbon in benzoxazine is replaced by nitrogen and they 
have shown promising biological activity.3 Halo-pyridines 
are important building blocks in organic synthesis as they 
easily react with various nucleophiles. This reactive nature 
can be attributed to the high electronegativity of halogen 
atom which makes carbon–halogen bond prone to 
nucleophilic aromatic substitutions (SNAr). In general, 
substituted 2- and 4-halopyridines are attractive 
intermediates in synthetic and medicinal chemistry and are 
extensively used for the construction of various pyride-
based heterocycles including N-fused heterocycles.4 This 
electrophilic character of halopyridines has also been used in 
pyrido-oxazines syntheses.5 Several other synthetic 
protocols are also available in the literature.6 However 
there is a need to develop alternative methods in view of 
the importance of these scaffolds. In continuation with our 
ongoing program of synthesizing brominated marine 
natural product and their analogs,7 we wish to report a 
simple strategy for synthesis of functionalized pyrido-
oxazines employing a tandem SN2 and SNAr reaction. 
We have recently reported a synthesis of 
dihydrobenzoxazines and tetrahydrobenzoxazepines by 
employing complementary ambiphile pairing (CAP) and 
complementary pairing (CP) method via an interesting N-
dealkylative SNAr substitution reaction with activated 
aromatic halides.8 We thought of extending the same 
protocol for the synthesis of pyrido-oxazines. Unlike our 
previous work,8 pyridine moiety does not require an EWG 
activating group and therefore  2,4,6-tribromopyridin-3-ol 
1 and 3-chloro-N,N-dimethylpropan-1-amino 
hydrochloride 1ab appeared to be suitable substrate pair 
for this study. 
 
Figure 1 Important pyridine motif. 
Accordingly when 2,4,6-tribromopyridin-3-ol 1 was treated 
with 3-chloro-N,N-dimethylpropan-1-amino hydrochloride 
1ab, we observed the formation of regioisomeric seven 
membered N-demethylative products 1a and 1b in 44% 
overall yield. Similarly treatment of 1 with 2-chloro-N,N-
dimethylethanamino hydrochloride 2ab gave 2a and 2b in 
54% overall yield (Scheme 1). 
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Scheme 1 N-dealkylative cyclisation  
Alternatively, transformation of 1 to 6a,b would furnish bis-
electrophilic species which upon treatment with primary 
amines would provide the corresponding products, sans N-
demethylative pathway.8 Phenol 1 on treatment with 1,2-
dibromoethane gave bis-electrophile 6a in 54% yield and 
similar treatment of 1,3-dibromopropane gave 6b in 85% 
yield (Scheme 2). When 6a was subjected to aqueous 
methylamine 2ba in DMF at ambient temperature, cyclized 
products 2a and 2b were obtained in 80% overall yield 
(Scheme 3). To check scope of the reaction 6a was then 
subjected to variety of primary amines. This methodology 
tolerates functional group like Allyl 2c, 2d cyclopropyl 2g, 
2h and benzyl 2o, 2p (figure 2). Interestingly chiral amine 
afforded cyclic product 2k, 2l in good yield. 2-
(Aminomethyl)aniline 2qr which has two free –NH2 groups 
reacted to give a product with selectively benzyl amino 
group getting involved in the reaction to give product 2q, 
2r in good yield. Biologically important indole derivative 
2u, 2v were prepared in good yield. This methodology has 
also been used to prepare seven membered pyrido-oxazine 
1a, 1b, 1c and 1d in good yield. 
 
Figure 2 Characteristic 13C value of 2- and 4-isomer and single crystal X-ray 
structure of compound 2p (CCDC 1584958) 
 
 The structural assignment for the two regioisomeric (2- or 
4-cyclised) products is based on the characteristic 13C NMR 
values of methine carbons in the pyridine ring of the two 
isomers. As depicted in Figure 2, for 2-cyclised isomer 
methine carbon appears in the range δ 119.6-117.6 and 4-
cyclised isomer shows up between d 110.4-108.1. An 
unambiguous conformation was obtained by single crystal 
x-ray analysis of 2p (Figure 2). A similar difference, δ 119.8-
121.5 for 2-cyclised isomer and δ 112.4-114.3 for 4-cyclised 
isomer, allowed assignment for seven membered 
derivatives. 
 
Scheme 2 Synthesis of bis-electrophilic intermediate 6a and 6b 
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Scheme 3 cyclization with primary amine 
After having pyrido-oxazine products in hand we thought of 
utilizing bromine atoms at 2,6- or 4,6-positions for further 
functionalisation through standard procedures. Application 
of Suzuki–Miyaura reaction furnished biarylated pyrido-
oxazine 7a-7g in good yield (Scheme 4). Similarly, Stille 
coupling between pyrido-oxazine 2b and 2-
(tributylstannyl)pyridine 8 in presence of Pd(PPh3)4 
gave terpyridine ligand 8a in good yield (Scheme 5). 
This reaction was then extended to 1a, 2l, 2k, 2c, 2g to 
obtain terpyridine ligands 8b, 8c, 8d, 8e, 8f in good 
yield.  
 
Synthesis Paper / PSP / Special Topic 
Template for SYNTHESIS © Thieme  Stuttgart · New York 2018-08-01 page 4 of 10 
 
Scheme 4 Synthesis of biarylated pyrido-oxazine 
 
 
Scheme 5 Synthesis of terpyridine ligand 
In conclusion, we have developed a method for the 
synthesis of pyrido-oxazine via tandem SN2 and SNAr 
reaction in good yield. We were successfully able to 
functionalize pyrido-oxazine formed into biarylated 
pyrido-oxazine and terpyridines using Suzuki and stille 
coupling reactions in moderate to good yield 
The experimental section has no title; please leave this line here. 
In this section the preparations of all the compounds that have been 
made in the course have been discussed. For the experiments, all starting 
material and reagents are purchased from standard commercial sources 
or were prepared in laboratory. All the glassware were cleaned with 
soap water followed by acetone and dried in hot air oven at 100 ˚C for 
2h. Solvents were distilled prior to use. IR spectra were recorded on the 
Bruker Tensor 37 (FTIR) spectrophotometer.1H NMR spectra were 
recorded on Bruker Avance 400 (400 MHz) spectrometer at 295K in 
CDCl3; chemical shifts value (δ ppm) and coupling constants (Hz) are 
reported in standard fashion with reference to either tetramethylsilane 
(TMS) (δ-H = 0.00 ppm) or CHCl3 (δ-H = 7.26 ppm). 13C NMR spectra 
were recorded on Bruker Avance 400 (100 MHz) spectrometer at 298K 
in CDCl3; chemical shifts (δ ppm) are reported relative to CHCl3 [(δ-C = 
77.00 ppm) central line of triplet]. In 13C NMR the nature of carbons (C, 
CH, CH2, and CH3) was determined by recording the DEPT- 135 spectra. 
In 1H NMR, the following abbreviations were used throughout the 
experimental; s = singlet, d = doublet, t = triplet, q = quartet, qui = 
quintet, m = multiplet and br. s = broad singlet. The assignment of the 
signals was confirmed by 1H, 13C and DEPT spectra. High resolution mass 
spectra (HRMS) were recorded on Agilent 6538 UHD Q-TOF using 
multimode source in +ESI method at the Department of Chemistry, 
Indian Institute of Technology Hyderabad, India. Reactions were 
monitored by TLC on silica gel (254 mesh) using a combination of 
hexane and ethyl acetate as eluents. 
2,4,6-tribromopyridin-3-ol (1) 
To solution of 3-hydroxy pyridine (5 g, 52.5 mmol) in H2O (60 mL) was 
added bromine (10.84 mL, 210 mmol) at 0 oC and reaction mixture was 
stirred at rt for 12 h. Solid formed was filtered through suction filter. 
Solid product 1 collected was used without further purification. 
 (12 g, 69%); Yellow solid; mp: 74-76 oC; Rf = 0.5 (60% EtOAc in hexane); 
IR (neat): 3743, 3677, 3617, 1698, 1540, 1516, 1459; 
 1H NMR (400 MHz, CDCl3) δ = 7.60 (s, 1H), 6.02 (s, 1H); 
 13C NMR (100 MHz, CDCl3) δ = 147.4, 131.1, 129.7, 128.6, 120.8; 
 HRMS (ESI+) m/z calculated for C5H2Br3NO [M]+: 330.7666; found: 
330.775.  
General procedure and spectral data for compound 1a, 1b, 2a, 2b 
via N-dealkylative cyclisation. 
To stirred suspension of K2CO3 (167 mg, 1.208 mmol) in DMF (1 mL) 
was added 2,4,6-tribromopyridin-3-ol 1 (100 mg , 0.302 mmol) and 3-
chloro-N,N-dimethylpropan-1-amine hydrochloride 1ab (86 mg, 0.604 
mmol) and after being stirred for 10 h at 120 oC, to the reaction mixture 
was then added water (3 mL) and extracted with EtOAc (8x3 mL). The 
EtOAc layer was washed with water (3 mL) and brine (3 mL) solutions, 
dried over sodium sulfate and evaporated under reduced pressure. The 
resulting residue was purified over silica gel chromatography (20% 
EtOAc in hexane) to give compound 1a (38 mg, 39%) and 1b (5 mg, 5%) 
as colourless solid.  
7,9-dibromo-5-methyl-2,3,4,5-tetrahydropyrido[3,2-
b][1,4]oxazepine (1a) 
 (38 mg, 39%); white solid; mp: 92-94 oC; Rf = 0.5 (10% EtOAc in 
hexane); 
IR (neat); 2922, 1562, 1522, 1416, 1363, 1192, 1042, 962, 759;  
1H NMR (400 MHz, CDCl3) δ = 6.91 (s, 1H), 4.24 (t, J = 6.4 Hz, 2H), 3.56 - 
3.48 (m, 2H), 3.06 (s, 3H), 2.19 - 2.04 (m, 2H);  
13C NMR (100 MHz, CDCl3) δ = 154.3, 140.5, 131.4, 125.1, 119.8, 70.3, 
50.0, 39.5, 28.0; 




 (5 mg, 5%); white solid; mp: 98-100 oC; Rf = 0.5 (10% EtOAc in hexane); 
 1H NMR (400 MHz, CDCl3) δ = 6.57 (s, 1H), 4.31 - 4.22 (m, 2H), 3.62 - 
3.53 (m, 2H), 2.99 - 2.90 (m, 3H), 2.21 - 2.09 (m, 2H); 
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13C NMR (100 MHz, CDCl3) δ = 151.7, 141.2, 134.0, 133.9, 112.5, 70.2, 
51.9, 40.8, 28.0;  
IR (neat); 2925, 1564, 1511, 1426, 1382, 1264, 1196, 1040; 




 (38 mg, 41%); white solid; mp: 82-84 oC; Rf = 0.5 (10% EtOAc in 
hexane); 
IR (neat); 2939, 2892, 1580, 1531, 1510, 1451, 1415, 1357, 1302, 1211, 
1051, 922, 778, 695;  
 1H NMR (400 MHz, CDCl3) δ = 6.84 (s, 1H), 4.3(t, J= 4.4 Hz, 2H), 3.48 (t, 
J=4.4 Hz, 2H), 3.11 (s, 3H);  
13C NMR (100 MHz, CDCl3) δ =147.8, 136.4, 129.7, 118.6, 117.9, 64.4, 
47.7, 36.2; 




(12 mg, 36%); white solid; mp: 138-140 oC; Rf = 0.2 (10% EtOAc in 
hexane);  
IR (neat); 2945, 2882, 1581, 1509, 1461, 1426, 1352, 1290, 1249, 1217, 
1119, 1052, 926, 822, 790; 
1H NMR (400 MHz, CDCl3) δ = 6.56 (s, 1H), 4.31 (t, J=4.4 Hz, 2H), 3.43 (t, J 
=4.4 Hz, 2H), 2.97 (s, 3H); 
 13C NMR (100 MHz, CDCl3) δ =144.0, 136.8, 131.6, 126.9, 108.5, 64.1, 
48.0, 37.9; 
 HRMS (ESI+) m/z calculated for C17H16Br2N3O [M+H]+: 308.9061; found: 
308.9053. 
2,4,6-tribromo-3-(2-bromoethoxy)pyridine (6a) 
To stirred suspension of K2CO3 (4.99 g, 36.15 mmol) in DMF (35 mL) was 
added 2,4,6-tribromopyridin-3-ol 1 (4 g , 12.05 mmol) and stirred at 0 oC 
for 0.5 h. Then added 1,2-dibromoethane (11.32 g, 60.25 mmol) and 
after being stirred for 12 h at 80 oC to the reaction mix was added water 
(100 mL) and extracted with EtOAc (80x2 mL). The EtOAc layer was 
washed with water (12x3 mL) and brine (20x2 mL) solution, dried over 
sodium sulfate and evaporated under reduced pressure. The resulting 
residue was purified over silica gel chromatography (10% EtOAc in 
hexane) to give compound 2,4,6-tribromo-3-(2-bromoethoxy)pyridine 3 
(2.45 g, 46%); colourless solid mp: 60-62 oC; Rf = 0.5 (10% EtOAc in 
hexane);  
(IR neat); 2924, 1516, 1412, 1310, 985, 742; 
1H NMR (400 MHz, CDCl3) δ =7.66 (s, 1H), 4.35 (t, J=6.5 Hz, 2H), 3.72 (t, 
J=6.5 Hz, 2H);  
13C NMR (100 MHz, CDCl3) δ = 150.2, 136.7, 134.8, 131.5, 129.7, 72.9, 
28.6; 
HRMS (ESI+) m/z calculated for C7H6Br4NO [M+H]+: 439.7142; found: 
439.7134. 
2,4,6-tribromo-3-(3-bromopropoxy)pyridine (6b) 
To stirred suspension of K2CO3 (2.5 g, 18.12 mmol) in DMF (20 mL) was 
added 2,4,6-tribromopyridin-3-ol 1 (2 g , 6.02 mmol) and stirred at 0 oC 
for 0.5 h. Then added 1,3-dibromopropane (6.08 g, 30.1 mmol) and after 
being stirred for 4 h at 80 oC to the reaction mix was added water (40 
mL) and extracted with EtOAc (30x2 mL). The EtOAc layer was washed 
with water (20 mL) and brine (20 mL) solution, dried over sodium 
sulfate and evaporated under reduced pressure. The resulting residue 
was purified over silica gel chromatography (20% EtOAc in hexane) to 
give compound 2,4,6-tribromo-3-(3-bromopropoxy)pyridine 4 (1.67 g, 
61%); colourless solid; mp: 40-42 oC; Rf = 0.7 (20% EtOAc in hexane); 
(IR neat); 2950, 1517, 1416, 1311, 996, 742; 
 1H NMR (400 MHz, CDCl3) δ =7.65 (s, 1H), 4.18 (t, J=5.6 Hz, 2H), 3.70 (t, 
J=6.4 Hz, 2H), 2.41 (quin, J=6.4, 5.7 Hz, 2H); 
 13C NMR (100 MHz, CDCl3) δ = 150.5, 136.9, 134.4, 131.5, 129.8, 71.4, 
33.17, 29.5; 
HRMS (ESI+) m/z calculated for C8H7Br4NO [M]+: 452.7220; found: 
452.7368. 
General Procedure and spectral data for product compounds 2c- 2x 
To solution of 2,4,6-tribromo-3-(2-bromoethoxy)pyridine 6a (100 mg, 
0.228 mmol) in DMF (1 mL) was added benzyl amine (73 mg, 0.684 
mmol) and the reaction mixture was stirred for 36 h at rt. To the reaction 
mixture was then added water (3 mL) and extracted with EtOAc (12x3 
mL) The combined organic phases were washed with water (3 mL), 
brine (3 mL), dried over Na2SO4 and concentrated in vacuo The resulting 
crude was purified over silica gel column chromatography with 10-20% 
EtOAc in hexane, which afforded product 2o (52 mg, 59%) & 2p (26 mg, 
30%). 
4-allyl-6,8-dibromo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine (2c) 
 (45 mg, 59%); white solid; mp: 54-56 oC; Rf = 0.6 (10% EtOAc in 
hexane);  
IR (neat); 3093, 2939, 1578, 1534, 1502, 1449, 1418, 1357, 1305, 1255, 
1213, 1094, 1040, 992, 925, 806, 673;  
1H NMR (400 MHz, CDCl3) δ = 6.85 (s, 1H), 5.89 - 5.72 (m, 1H), 5.27 - 5.16 
(m, 2H), 4.27 (t, J= 4.4 Hz, 2H), 4.21 (d, J= 5.9 Hz, 2H), 3.44 (t, J=4.4 Hz, 
2H); 
 13C NMR (100 MHz, CDCl3) δ = 145.8, 135.1, 131.7, 128.5, 117.6, 117.2, 
117.1, 63.4, 49.1, 43.5;  
HRMS (ESI+) m/z calculated for C10H11Br2N2O [M+H]+: 334.9218; found: 
334.9212. 
1-allyl-5,7-dibromo-2,3-dihydro-1H-pyrido[3,4-b][1,4]oxazine (2d) 
 (26 mg, 34%); white solid; mp: 78-80 oC; Rf = 0.2 (10% EtOAc in 
hexane);  
IR (neat); 3086, 2874, 1576, 1528, 1503, 1454, 1402, 1352, 1287, 1246, 
1211, 1167, 1070, 1035, 925, 822, 796, 700, 662;  
1H NMR (400 MHz, CDCl3) δ = 6.58 (s, 1H), 5.78 (tdd, J = 5.0, 10.4, 17.2 
Hz, 1H), 5.33 - 5.11 (m, 2H), 4.3 (t, J=4.4 Hz, 2H), 3.91 (td, J = 1.7, 5.0 Hz, 2 
H), 3.46 (t, J = 4.4 Hz, 2H); 
 13C NMR (100 MHz, CDCl3) δ = 143.1, 136.7, 131.7, 130.2, 127.5, 118.1, 
108.7, 64.0, 52.8, 46.3;  
HRMS (ESI+) m/z calculated for C10H11Br2N2O [M+H]+: 334.9218; found: 
334.9212. 
6,8-dibromo-4-ethyl-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine (2e) 
 (42 mg, 57%); white solid; mp: 82-84 oC; Rf = 0.6 (10% EtOAc in 
hexane); 
IR (neat); 2932, 1578, 15051443, 1358, 1209, 1058, 930, 767;  
 1H NMR (400 MHz, CDCl3) δ = 6.82 (s, 1H), 4.31 - 4.23 (m, 2H), 3.64 (q, J 
= 7.2 Hz, 2H), 3.53 - 3.44 (m, 2H), 1.17 (t, J = 7.1 Hz, 3H);  
13C NMR (100 MHz, CDCl3) δ = 146.9, 136.1, 129.7, 118.0, 117.9, 64.3, 
44.7, 42.7, 11.7; 
HRMS (ESI+) m/z calculated for C9H11Br2N2O [M+H]+: 322.9218; found: 
322.9209. 
5,7-dibromo-1-ethyl-2,3-dihydro-1H-pyrido[3,4-b][1,4]oxazine (2f) 
 (22 mg, 30%); white solid; mp: 78-80 oC; Rf = 0.2 (10% EtOAc in 
hexane); 
IR (neat); 2932, 1578, 1505, 1423, 1358, 1209, 1058, 930, 767;  
 1H NMR (400 MHz, CDCl3) δ = 6.59 (s, 1H), 4.32 - 4.24 (m, 2H), 3.46 - 
3.42 (m, 2H), 3.36 (q, J = 7.3 Hz, 2H), 1.27 - 1.12 (m, 3H); 
 13C NMR (100 MHz, CDCl3) δ = 142.8, 136.8, 131.7, 127.4, 108.1, 63.9, 
45.5, 45.0, 10.9; 
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 (30 mg, 39%); white solid; mp: 91-93 oC; Rf = 0.5 (10% EtOAc in 
hexane); 
IR (neat); 2979, 1575, 1485, 1443, 1354, 1219, 1118, 1023; 
 1H NMR (400 MHz, CDCl3) δ = 6.93 (s, 1H), 4.31 - 4.23 (m, 2H), 3.51 - 
3.43 (m, 2H), 2.68 (tt, J = 3.5, 7.0 Hz, 1H), 0.93 - 0.82 (m, 2H), 0.68 - 0.58 
(m, 2H); 
 13C NMR (100 MHz, CDCl3) δ = 148.0, 136.6, 129.5, 119.6, 117.9, 65.3, 
45.7, 30.5, 7.6;  




 (33 mg, 43%); white solid; mp: 142-144 oC; Rf = 0.2 (10% EtOAc in 
hexane);  
IR (neat); 2958, 1574, 1487, 1451, 1348, 1251, 1116, 1026, 823; 
1H NMR (400 MHz, CDCl3) δ = 7.05 (s, 1H), 4.28 (br. s., 2H), 3.42 (br. s., 
2H), 2.48 (br. s., 1H), 0.99 - 0.88 (m, 2H), 0.69 (br. s., 2H);  
13C NMR (100 MHz, CDCl3) δ = 144.4, 137.2, 131.1, 127.1, 110.4, 64.9, 
45.7, 31.1, 8.1; 




 (41 mg, 54%); gummy solid; Rf = 0.5 (10% EtOAc in hexane);  
IR (neat); 2927, 1578, 1504, 1423, 1357, 1300, 1211, 1061, 938, 746;  
1H NMR (400 MHz, CDCl3) δ = 6.81 (s, 1H), 4.29 - 4.22 (m, 2H), 3.59 - 3.43 
(m, 4H), 1.70 - 1.55 (m, 2H), 0.93 (t, J = 7.3 Hz, 3H); 
 13C NMR (100 MHz, CDCl3) δ = 147.1, 135.8, 131.5, 129.6, 117.9, 64.3, 
49.6, 45.5, 20.1, 11.4;  




 (24 mg, 31%); white solid; mp: 67-69 oC; Rf = 0.2 (10% EtOAc in 
hexane); 
IR (neat); 2933, 1505, 1403, 1065, 939, 797;  
1H NMR (400 MHz, CDCl3) δ = 6.57 (s, 1H), 4.32 - 4.23 (m, 2H), 3.49 - 3.42 
(m, 2H), 3.28 - 3.19 (m, 2H), 1.65 (sxt, J = 7.4 Hz, 2H), 0.97 (t, J = 7.3 Hz, 
3H); 
 13C NMR (100 MHz, 400 MHz, CDCl3) δ = 143.1, 136.6, 131.7, 127.4, 
108.1, 63.8, 52.3, 46.5, 19.5, 11.4; 




 (47 mg, 52%); gummy solid; Rf = 0.2 (10% EtOAc in hexane); 
IR (neat); 2938, 1574, 1488, 1415, 1353, 1211, 1064, 775, 699;  
 1H NMR (400 MHz, CDCl3) δ = 7.37 - 7.23 (m, 5H), 6.87 (s, 1H), 6.20 (q, J 
= 7.0 Hz, 1H), 4.25 - 4.16 (m, 1H), 4.03 (ddd, J = 2.9, 7.5, 10.6 Hz, 1H), 
3.32 (ddd, J = 3.2, 7.5, 12.8 Hz, 1H), 3.04 (ddd, J = 2.7, 4.5, 12.8 Hz, 1H), 
1.61 - 1.50 (m, 3H);  
13C NMR (100 MHz, CDCl3) δ = 146.7, 140.2, 136.0, 131.5, 129.5, 128.5, 
127.5, 127.4, 118.3, 72.9, 64.6, 51.0, 39.3, 28.6, 15.1;  




(24 mg, 26%); white solid; mp: 106-108 oC; Rf = 0.3 (10% EtOAc in 
hexane); 
IR (neat); 2938, 1574, 1488, 1415, 1353, 1211, 1064, 775, 699; 
 1H NMR (400MHz, CDCl3) δ = 7.44 - 7.21 (m, 5H), 6.80 (s, 1H), 5.08 (q, J = 
6.8 Hz, 1H), 4.31 - 4.21 (m, 1H), 4.09 (ddd, J = 2.9, 7.7, 10.9 Hz, 1H), 3.30 
(ddd, J = 3.2, 7.5, 12.8 Hz, 1H), 3.17 - 3.04 (m, 1H), 1.68 - 1.52 (m, 3H);  
13C NMR (100 MHz, CDCl3) δ = 143.2, 139.0, 136.8, 131.8, 129.0, 128.1, 
127.9, 126.8, 108.5, 64.2, 55.0, 40.1, 15.8;  




(52 mg, 59%); gummy solid; Rf = 0.3 (10% EtOAc in hexane); 
IR (neat); 2836, 2899, 1576, 1533, 1500, 1445, 1417, 1356, 1298, 1210, 
1048, 915, 737, 697; 
 1H NMR (400 MHz, CDCl3) δ = 7.34-7.25 (m, 5H), 6.88 (s, 1H), 4.80 (s, 
2H), 4.21 (t, J= 4.4 Hz, 2H), 3.37 (t, J= 4.4 Hz, 2H); 
 13C NMR (100 MHz, CDCl3) δ =147.0, 136.9, 136.0, 129.5, 128.7, 128.2, 
127.6, 118.8, 118.5, 64.4, 50.9, 44.5; 




 (26 mg, 30%); white solid; mp: 142-144 oC ; Rf = 0.2 (10% EtOAc in 
hexane); 
IR (neat); 2931, 2874, 1574, 1528, 1501, 1453, 1352, 1246, 1072, 922, 
799, 733, 697; 
 1H NMR (400 MHz, CDCl3) δ = 7.45 - 7.29 (m, 3H), 7.24 - 7.14 (m, 2H), 
6.65 (s, 1H), 4.51 (s, 2H), 4.31 (t, J=4.4 Hz, 2H), 3.48 (t, J=4.4 Hz, 2H); 
 13C NMR (100 MHz, CDCl3) δ = 143.4, 136.7, 135.0, 131.8, 129.2, 128.1, 
127.7, 126.8, 108.7, 64.1, 53.9, 46.5; 




 (48 mg, 53%); white solid; mp: 81-83 oC; Rf = 0.7 (10% EtOAc in 
hexane);  
1H NMR (400 MHz, CDCl3) δ = 7.18 - 7.04 (m, 2H), 6.87 (s, 1H), 6.74 - 6.63 
(m, 2H), 4.68 (s, 2H), 4.55 (br. s., 2H), 4.21 (t, J=4.4 Hz, 2H), 3.45 (t, J=4.4 
Hz, 2H);  
13C NMR (100 MHz, CDCl3) δ = 146.9, 146.2, 136.2, 131.5, 129.4, 129.2, 
119.8, 118.7, 118.6, 117.4, 115.9, 64.3, 49.0, 44.5;  
IR (neat); 3450, 3339, 3220, 3010, 2895, 1631, 1575, 1502, 1443, 1354, 
1298, 1251, 1206, 1162, 1111, 1041, 908, 747; 




 (23 mg, 25%); white solid; mp: 164-166 oC; Rf = 0.2 (10% EtOAc in 
hexane);  
IR (neat); 3743, 2929, 1572, 1504, 1456, 1401, 1354, 1247; 
1H NMR (400 MHz, CDCl3) δ = 7.19 (dt, J = 1.2, 7.7 Hz, 1H), 7.01 (d, J = 7.3 
Hz, 1H), 6.82 - 6.72 (m, 3H), 4.34 (s, 2H), 4.3 (t, J=4.4 Hz, 2H), 3.71 (br. s., 
2H), 3.29 (t, J=4.4 Hz, 2H); 
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 13C NMR (100 MHz, CDCl3) δ = 144.8, 143.6, 137.2, 131.7, 129.5, 129.1, 
127.7, 119.0, 118.3, 116.4, 109.0, 64.5, 50.9, 44.5; 




 (40 mg, 39%); gummy solid; Rf = 0.3 (25% EtOAc in hexane);  
IR (neat); 3743, 3616, 3346, 2929, 1698, 1577, 1518, 1360, 1167, 1067; 
1H NMR (400 MHz, CDCl3) δ = 6.83 (s, 1H), 5.56 (br. s., 1H), 4.25 (t, 
J=4.4Hz, 2H), 3.64 (t, J = 6.4 Hz, 2H), 3.48(t, J=4.4 Hz, 2H), 3.10 (q, J = 6.4 
Hz, 2H), 1.74 (quin, J = 6.1 Hz, 2H), 1.48 - 1.40 (m, 9H); 
 13C NMR (100 MHz, CDCl3) δ = 156.2, 147.3, 135.9, 129.5, 118.4, 78.9, 
64.2, 45.5, 45.0, 36.0, 28.5, 27.4; 




 (27 mg, 26%); white solid; mp: 121-123 oC; Rf = 0.2 (25% EtOAc in 
hexane);  
IR (neat); 3343, 2773, 2933, 1694, 1577, 1520, 1459, 1401, 1359, 1281, 
1248, 1167, 1065, 930, 796; 
1H NMR (400 MHz, CDCl3) δ =6.55 (s, 1 H), 4.70 (br. s., 1H), 4.27 (t, J=4.4 
Hz, 2H), 3.45 (t, J=4.4 Hz, 2 H), 3.33 (t, J= 7.3 Hz, 2 H), 3.22 - 3.15 (m, 2 H), 
1.80 (quin, J = 7.0 Hz, 2 H), 1.48 - 1.37 (m, 9 H); 
 13C NMR (100 MHz, CDCl3) δ = 156.1, 142.9, 136.8, 131.6, 127.5, 108.1, 
79.7, 63.9, 48.1, 46.5, 38.0, 28.4(3XCH3), 27.0; 




 (57 mg, 57%); white solid; mp: 62-64 oC; Rf = 0.3 (25% EtOAc in 
hexane); 
IR (neat); 3413, 2932, 1577, 1532, 1504, 1450, 1421, 1357, 1258, 1210, 
1088, 1041, 927, 742; 
 1H NMR (400 MHz, CDCl3) δ = 7.85 (br. s., 1H), 7.71 (d, J = 7.8 Hz, 1H), 
7.24 (d, J = 7.8 Hz, 1H), 7.16 - 7.03 (m, 2H), 6.88 (d, J = 2.0 Hz, 1H), 6.77 
(s, 1H), 4.02 - 3.93 (m, 2H), 3.75 (t, J=7.3 Hz, 2H), 3.27 - 3.19 (m, 2H), 
2.97 (t, J=7.8 Hz, 2H) ; 
 13C NMR (100 MHz, CDCl3) δ =146.8, 136.3, 136.0, 129.9, 127.5, 122.2, 
122.0, 119.5, 119.2, 118.1, 117.9, 113.3, 111.2, 64.3, 49.3, 46.3, 22.9; 




(30 mg, 30%); gummy solid; Rf = 0.1 (25% EtOAc in hexane);  
IR (neat); 3400, 1658, 1578, 1523, 1355, 1247, 1021, 999, 822, 759, 620; 
1H NMR (400 MHz, DMSO-d6) δ = 10.85 (br. s., 1H), 7.55 (d, J = 7.8 Hz, 
1H), 7.35 (d, J = 7.8 Hz, 1H), 7.20 (d, J = 2.4 Hz, 1H), 7.08 (dt, J = 1.2, 7.5 
Hz, 1H), 7.02 - 6.94 (m, 1H), 6.74 (s, 1H), 4.11 (t, J = 4.4 Hz, 2H), 3.64 (t, J 
= 7.1 Hz, 2H), 3.37 - 3.32 (m, 2H), 2.96 (t, J = 7.1 Hz, 2H); 
 13C NMR (100 MHz, DMSO-d6) δ = 143.3, 136.2, 136.1, 130.8, 127.0, 
126.1, 123.3, 121.0, 118.4, 118.0, 111.5, 110.8, 107.8, 63.5, 50.4, 45.8, 
21.4; 




 (47 mg, 59%); gummy solid; Rf = 0.4 (10% EtOAc in hexane);  
IR (neat); 2925, 1694, 1513, 1460, 1211; 
1H NMR (400 MHz, CDCl3) δ = 6.81 (s, 1H), 4.26 (t, J =4.4 Hz, 2H), 3.58 (t, J 
= 7.1 Hz, 2H), 3.49 (t, J =4.4 Hz, 2H), 1.58 (quin, J = 7.1, 15 Hz, 2H), 1.35 
(qd, J = 7.2, 15.0 Hz, 2H), 0.96 (t, J = 7.3 Hz, 3H) ; 
 13C NMR (100 MHz, CDCl3) δ = 147.1, 135.9, 131.5, 129.7, 117.9, 64.3, 
47.6, 45.4, 29.0, 20.1, 13.9; 
 HRMS (ESI+) m/z calculated for C11H15Br2N2O [M+H]+: 350.9531; found: 
350.9516. 
5,7-dibromo-1-butyl-2,3-dihydro-1H-pyrido[3,4-b][1,4]oxazine (2x) 
 (24 mg, 30%); white solid; mp: 47-49 oC; Rf = 0.2 (10% EtOAc in 
hexane);  
IR (neat); 2956, 2868, 1577, 1505, 1459, 1403, 1354, 1246, 1210, 1066, 
920, 818, 698; 
1H NMR (400 MHz, CDCl3) δ = 6.56 (s, 1H), 4.26 (t, J=4.4 Hz, 2H), 3.44 (t, J 
= 4.4 Hz, 2H), 3.27 (t, J= 7.8 Hz, 2H), 1.59 (quin, J= 7.3 Hz, 2H), 1.45 - 1.29 
(m, 2H), 0.97 (t, J = 7.3 Hz, 3H);  
 13C NMR (100 MHz, CDCl3) δ = 143.1, 136.6, 131.7, 127.4, 108.1, 63.8, 
50.5, 46.5, 28.2, 20.2, 13.9; 
HRMS (ESI+) m/z calculated for C11H15Br2N2O [M+H]+: 350.9531; found: 
350.952. 
7,9-dibromo-5-cyclopropyl-2,3,4,5-tetrahydropyrido[3,2-
b][1,4]oxazepine (1c)  
(25 mg, 33%); white solid; mp: 60-62 oC; Rf = 0.6 (10% EtOAc in hexane); 
IR (neat); 1559, 1526, 1467, 1434, 1370, 1349, 1308, 1278, 1203, 1094, 
1061, 1023, 949, 878, 820, 777, 689; 
 1H NMR (400 MHz, CDCl3) δ = 7.05 (s, 1H), 4.16 (t, J = 6.1 Hz, 2H), 3.61 - 
3.52 (m, 2H), 2.80 (tt, J = 3.5, 7.0 Hz, 1H), 2.01 (quin, J = 6.0 Hz, 2H), 0.87 
- 0.76 (m, 2H), 0.57 - 0.48 (m, 2H); 
 13C NMR (100 MHz, CDCl3) δ = 155.1, 141.3, 131.2, 125.1, 121.5, 70.3, 
50.2, 33.8, 29.5, 8.3;  




(23 mg, 36%); white solid; mp: 106-108 oC; Rf = 0.2 (10% EtOAc in 
hexane); 
IR (neat); 3086, 2956, 1562, 1518, 1444, 1385, 1336, 1281, 1234, 1062, 
1025, 990, 951, 836, 689; 
 1H NMR (400 MHz, CDCl3) δ =7.01 (s, 1H), 4.18 (t, J = 5.8 Hz, 2H), 3.64 (t, 
J = 5.8 Hz 2H), 2.55 (tt, J = 3.3, 6.7 Hz, 1H), 2.05 (quin, J = 6.0 Hz, 2H), 0.94 
- 0.83 (m, 2H), 0.67 - 0.58 (m, 2H); 
 13C NMR (100 MHz, CDCl3) δ = 152.1, 141.5, 133.7, 133.2, 114.3, 70.2, 
51.4, 34.0, 29.5, 9.0; 
 HRMS (ESI+) m/z calculated for C11H13Br2N2O [M+H]+: 348.9374; found: 
348.9366. 
General Procedure and spectral data for product compound 7a-7g 
To solution of 5,7-dibromo-1-methyl-2,3-dihydro-1H-pyrido[3,4-
b][1,4]oxazine 2b (40 mg, 0.129 mmol) in dioxane (1 mL) was added 
Pd(PPh3)4 (14 mg, 0.0129 mmol), o-tolylboronic acid and aq 2M K2CO3 
(0.2 mL). The reaction mixture was stirred for 8 h at 80 oC. To the 
reaction mixture was then added water (4 mL) and extracted with EtOAc 
(12x3 mL) The combined organic phases were washed with brine (3 
mL), dried over Na2SO4 and concentrated in vacuo. The resulting crude 
was purified over silica gel column chromatography with 10% EtOAc in 
hexane, which afforded product 7g (32 mg, 74%) 
4-benzyl-6,8-diphenyl-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine 
(7a) 
11 mg of 2o gave (9 mg, 82%); white solid; mp: 144-146 oC; Rf = 0.5 
(10% EtOAc in hexane);  
IR (neat); 1693, 1648, 1515, 1462, 756; 
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1H NMR (400 MHz, CDCl3) δ = 8.05 - 7.97 (m, 2H), 7.63 (dd, J = 1.2, 8.6 Hz, 
2H), 7.51 - 7.23 (m, 11H), 7.12 (s, 1H), 5.07 (s, 2H), 4.26 - 4.18 (m, 2H), 
3.51 - 3.42 (m, 2H); 
 13C NMR (100 MHz, CDCl3) δ = 146.9, 146.8, 139.7, 138.6, 135.6, 135.0, 
129.2, 128.6, 128.4, 128.2, 127.9, 127.7, 127.2, 126.2, 111.1, 64.3, 51.0, 
45.1; 




 (23 mg, 59%); white solid; mp: 130-132 oC; Rf = 0.4 (10% EtOAc in 
hexane); 
 IR (neat); 2930, 1589, 1507, 1235, 774, 696; 
 1H NMR (400 MHz, CDCl3) δ = 7.99 (d, J = 7.8 Hz, 4H), 7.42 (t, J = 7.3 Hz, 
4H), 7.34 (d, J = 4.4 Hz, 2H), 6.91 (s, 1H), 4.26 (br. s., 2H), 3.41 (br. s., 2H), 
3.02 (s, 3 H);  
13C NMR (100 MHz, CDCl3) δ = 150.4, 144.1, 142.9, 140.5, 138.4, 129.6, 
128.5, 128.0, 128.0, 127.9, 126.8, 102.4, 64.0, 48.5, 38.2; 




62 mg of 2o gave (52 mg, 68%); white solid; mp:170-172 oC; Rf = 0.7 
(10% EtOAc in hexane); 
IR (neat); 3051, 1546, 1454, 1358, 1046, 778; 
 1H NMR (400 MHz, CDCl3) δ = 8.46 (d, J = 8.8 Hz, 1H), 7.93 - 7.74 (m, 5H), 
7.69 - 7.61 (m, 1H), 7.58 - 7.21 (m, 12H), 6.95 - 6.87 (m, 1H), 5.10 - 5.00 
(m, 1H), 4.97 - 4.85 (m, 1H), 4.16 - 4.03 (m, 2H), 3.50 - 3.33 (m, 2H);  
13C NMR (100 MHz, CDCl3) δ = 148.9, 146.7, 138.9, 138.5, 135.9, 134.9, 
134.2, 134.1, 133.6, 131.5, 131.4, 128.6, 128.4, 128.4, 128.3, 128.2, 127.3, 
127.2, 126.7, 126.3, 126.2, 125.9, 125.9, 125.6, 125.4, 125.4, 117.4, 64.2, 
51.0, 45.4;  




50 mg of 1a gave (47 mg, 96%); white solid; mp:89-91 oC; Rf = 0.7 (10% 
EtOAc in hexane); 
IR (neat); 2950, 1544, 1497, 1370, 1202, 1036, 952, 762, 696; 
 1H NMR (400 MHz, CDCl3) δ = 8.07 - 8.00 (m, 2H), 7.58 - 7.53 (m, 2H), 
7.49 - 7.33 (m, 6H), 7.17 (s, 1H), 4.20 (t, J = 6.1 Hz, 2 H), 3.60 - 3.49 (m, 
2H), 3.31 - 3.19 (m, 3H), 2.18 - 2.06 (m, 2H); 
 13C NMR (100 MHz, CDCl3) δ = 154.4, 148.1, 141.2, 140.6, 139.5, 137.5, 
129.2, 128.5, 128.1, 128.0, 127.9, 127.7, 126.4, 126.3, 112.6, 70.3, 50.6, 
40.0, 29.1;  




70 mg of 2k gave (63 mg, 91%); white solid; mp: 116-118 oC; Rf = 0.5 
(15% EtOAc in hexane); 
IR (neat); 2932, 1594, 1484, 1440, 1358, 1207, 1029, 771, 744, 695; 
 1H NMR (400 MHz, CDCl3) δ = 7.95 - 7.90 (m, 2H), 7.55 - 7.50 (m, 2H), 
7.38 - 7.13 (m, 11H), 7.00 (s, 1H), 6.56 (q, J = 6.8 Hz, 1H), 4.11 - 4.04 (m, 
1H), 3.95 (ddd, J = 2.9, 7.6, 10.5 Hz, 1H), 3.30 (ddd, J = 2.9, 7.7, 12.3 Hz, 
1H), 3.03 - 2.97 (m, 1H), 1.54 (d, J = 7.3 Hz, 3H);  
13C NMR (100 MHz, CDCl3) δ = 146.7, 146.5, 141.8, 139.8, 136.9, 135.6, 
134.9, 129.2, 128.4, 128.4, 128.2, 127.8, 127.7, 127.5, 127.0, 126.2, 110.7, 
64.4, 50.4, 39.5, 15.0; 




35 mg of 2h gave (16 mg, 47%); white solid; mp: 55-57 oC; Rf = 0.4 (15% 
EtOAc in hexane);  
 IR (neat); 2929, 1583, 1546, 1505, 1358, 1231, 1023, 1023, 776; 
1H NMR (400MHz, CDCl3) δ = 8.07 - 7.96 (m, 4H), 7.50 - 7.41 (m, 5H), 
7.39 - 7.32 (m, 2H), 4.38 - 4.19 (m, 2H), 3.53 - 3.38 (m, 2H), 2.60 - 2.45 
(m, 1H), 1.03 - 0.89 (m, 2H), 0.83 - 0.66 (m, 2H); 
 13C NMR (100 MHz, CDCl3) δ = 150.0, 144.3, 143.0, 140.5, 138.4, 137.8, 
129.6, 128.5, 127.9, 127.9, 127.8, 126.7, 115.3, 104.0, 64.8, 46.1, 31.3, 
8.1; 




 (32 mg, 74%); white solid; mp: 44-46 oC; Rf = 0.8 (10% EtOAc in 
hexane);  
IR (neat); 2926, 1601, 1454, 1359, 1206, 1036, 759; 
1H NMR (400 MHz, CDCl3) δ = 7.51 - 7.43 (m, 1H), 7.29 - 7.18 (m, 7H), 
6.55 (s, 1H), 4.27 - 4.20 (m, 2H), 3.50 - 3.42 (m, 2H), 3.18 (s, 3H), 2.50 (s, 
3H), 2.25 (s, 3H);  
13C NMR (100 MHz, CDCl3) δ = 149.4, 147.1, 140.7, 136.7, 136.3, 136.1, 
135.5, 134.6, 130.8, 129.9, 129.7, 129.5, 127.9, 127.4, 125.7, 125.6, 115.5, 
64.2, 48.2, 36.3, 21.1, 20.1; 
 HRMS (ESI+) m/z calculated for C22H23N2O [M+H]+: 331.1810; found: 
331.1802. 
General Procedure and spectral data for compound 8a-8f 
To solution of (S)-5,7-dibromo-1-(1-phenylethyl)-2,3-dihydro-1H-
pyrido[3,4-b][1,4]oxazine 2l (85 mg, 0.213 mmol) in toulene (2 mL) was 
added Pd(PPh3)4 (24 mg, 0.0213 mmol), 2-(tributylstannyl)pyridine 8 
and after degassing under argon, reaction mixture was stirred for 16 h at 
reflux. After completion of reaction which was checked by TLC. The 
reaction mixture was filtered through short pad of celite and 
concentrated in vacuo. The resulting crude was purified over 5% KF + 
silica gel column chromatography with 10% MeOH in DCM, which 
afforded product 8c (52 mg, 61%). 
1-methyl-5,7-di(pyridin-2-yl)-2,3-dihydro-1H-pyrido[3,4-
b][1,4]oxazine (8a) 
60 mg of 2b gave (55 mg, 92%); white solid; mp: 102-104 oC; Rf = 0.2 
(80% EtOAc in hexane); 
IR (neat); 2934, 1560, 1501, 1433, 1364, 1203, 1050, 791, 607; 
 1H NMR (400MHz, CDCl3) δ = 8.76 - 8.68 (m, 1H), 8.63 - 8.56 (m, 1H), 
8.35 - 8.28 (m, 1H), 8.11 (s, 1H), 7.82 - 7.78 (m, 1H), 7.71 (dtd, J = 2.0, 7.7, 
11.4 Hz, 2H), 7.24 - 7.14 (m, 2H), 4.33 - 4.26 (m, 2H), 3.55 - 3.46 (m, 2H), 
3.25 (s, 3H); 
 13C NMR (100 MHz, CDCl3) δ = 156.7, 154.7, 149.5, 148.9, 147.6, 145.8, 
138.1, 136.4, 135.8, 133.1, 124.9, 122.4, 122.3, 120.2, 112.0, 64.4, 47.8, 
36.3; 




48 mg of 1b gave (46 mg, 92%); white solid; mp: 98-100 oC; Rf = 0.2 
(25% EtOAc in hexane);  
1H NMR (400MHz, CDCl3) δ = 8.72 (td, J = 1.3, 4.8 Hz, 1H), 8.64 - 8.57 (m, 
1H), 8.37 - 8.29 (m, 1H), 8.11 (s, 1H), 7.78 - 7.68 (m, 3H), 7.28 - 7.16 (m, 
2H), 4.22 (t, J = 6.1 Hz, 2H), 3.55 (dd, J = 5.1, 6.6 Hz, 2H), 3.23 (s, 3H), 2.15 
- 2.08 (m, 2H); 
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 13C NMR (100 MHz, CDCl3) δ = 156.6, 155.4, 154.3, 149.4, 148.9, 147.3, 
142.9, 139.4, 136.5, 135.8, 125.0, 122.6, 122.4, 120.5, 113.4, 70.3, 50.5, 
40.0, 28.8;  
IR (neat); 2951, 1699, 1547, 1488, 1428, 1371, 1263, 1198, 1043, 792; 




 (52 mg, 61%); white solid; mp: 100-102 oC; Rf = 0.2 (5% MeOH in DCM); 
IR (neat); 1693, 1648, 1515, 1462, 754; 
 1H NMR (400MHz, CDCl3) δ = 8.79 - 8.73 (m, 1H), 8.62 - 8.58 (m, 1H), 
8.47 (d, J = 8.3 Hz, 1H), 8.07 (d, J = 1.0 Hz, 1H), 7.93 - 7.89 (m, 1H), 7.82 - 
7.70 (m, 2H), 7.41 - 7.32 (m, 4H), 7.31 - 7.25 (m, 2H), 7.21 (ddd, J = 1.0, 
4.9, 7.3 Hz, 1H), 5.57 (q, J = 6.8 Hz, 1H), 4.25 - 4.17 (m, 1H), 4.08 (ddd, J = 
2.9, 7.5, 10.6 Hz, 1H), 3.36 (ddd, J = 2.9, 7.6, 12.5 Hz, 1H), 3.14 - 3.03 (m, 
1H), 1.66 (d, J = 6.8 Hz, 3H);  
13C NMR (100 MHz, CDCl3) δ = 157.3, 156.7, 149.3, 148.9, 148.6, 144.1, 
142.2, 140.1, 139.4, 136.6, 136.0, 128.7, 127.6, 127.2, 124.9, 122.8, 122.5, 
121.2, 103.1, 64.2, 54.0, 39.8, 15.2; 




 (78 mg, 91%); white solid; mp: 118-120 oC; Rf = 0.2 (30% EtOAc in 
hexane); 
IR (neat); 2931, 1698, 1300, 1254, 1174, 1060, 789; 
 1H NMR (400MHz, CDCl3) δ = 8.75 - 8.71 (m, 1H), 8.60 (td, J = 1.0, 4.9 Hz, 
1H), 8.31 (d, J = 8.3 Hz, 1H), 8.11 (s, 1H), 7.82 - 7.77 (m, 1H), 7.71 (tt, J = 
1.8, 7.8 Hz, 2H), 7.46 - 7.41 (m, 2H), 7.37 - 7.30 (m, 2H), 7.28 - 7.20 (m, 
2H), 7.17 (ddd, J = 1.0, 4.9, 7.3 Hz, 1H), 6.61 (q, J = 6.8 Hz, 1H), 4.25 - 4.17 
(m, 1H), 4.09 (ddd, J = 2.9, 7.5, 10.6 Hz, 1H), 3.42 (ddd, J = 3.2, 7.3, 12.5 
Hz, 1H), 3.15 - 3.08 (m, 1H), 1.63 (d, J = 7.3 Hz, 3H); 
 13C NMR (100 MHz, CDCl3) δ = 156.8, 154.9, 149.5, 148.9, 146.4, 145.7, 
141.6, 137.7, 136.5, 135.9, 133.7, 128.5, 127.4, 127.1, 124.9, 122.5, 122.4, 
120.3, 111.7, 64.6, 50.7, 39.3, 15.0; 




96 mg of 2o gave (63 mg, 67%); white solid; mp: 150-152 oC; Rf = 0.2 
(35% EtOAc in hexane); 
IR (neat); 2928, 1560, 1497, 1436, 1362, 1204, 1043, 747; 
 1H NMR (400MHz, CDCl3) δ = 8.77 - 8.69 (m, 1H), 8.63 - 8.56 (m, 1H), 
8.30 - 8.23 (m, 1H), 8.14 (s, 1H), 7.83 - 7.78 (m, 1H), 7.69 (dtd, J = 2.0, 7.8, 
11.7 Hz, 2H), 7.40 - 7.35 (m, 2H), 7.34 - 7.29 (m, 2H), 7.28 - 7.20 (m, 2H), 
7.15 (ddd, J = 1.0, 4.8, 7.5 Hz, 1H), 5.04 (s, 2H), 4.31 - 4.17 (m, 2H), 3.52 - 
3.38 (m, 2H);  
13C NMR (100 MHz, CDCl3) δ = 156.7, 154.8, 149.5, 148.9, 146.8, 145.8, 
138.4, 137.7, 136.5, 135.9, 133.8, 128.6, 128.1, 127.2, 124.9, 122.5, 122.4, 
120.3, 112.1, 64.4, 51.2, 45.0;  




50 mg of 2g gave (44 mg, 89%); white solid; mp: 118-120 oC; Rf = 0.3 
(40% EtOAc in hexane);  
IR (neat); 2951, 1517, 1416, 1375, 1311, 1247, 997, 742; 
1H NMR (400MHz, CDCl3) δ = 8.75 - 8.71 (m, 1H), 8.60 (td, J = 1.2, 5.0 Hz, 
1H), 8.43 - 8.38 (m, 1H), 8.18 (s, 1H), 7.82 - 7.68 (m, 3H), 7.25 - 7.14 (m, 
2H), 4.37 - 4.19 (m, 2H), 3.60 - 3.43 (m, 2H), 2.80 - 2.63 (m, 1H), 1.03 - 
0.87 (m, 2H), 0.78 - 0.65 (m, 2H); 
 13C NMR (100 MHz, CDCl3) δ = 156.9, 154.8, 149.5, 148.8, 147.9, 145.7, 
138.3, 136.5, 135.8, 133.3, 124.9, 122.4, 122.3, 120.3, 112.9, 65.4, 46.0, 
31.0, 7.8;  
HRMS (ESI+) m/z calculated for C20H19N4O [M+H]+: 331.1559; found: 
331.1546. 
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